NewsBenzingaHUTCHMEDがファンレグラチニブの中国NDA受理と優先審査を発表、第II相登録試験の結果をサポート HUTCHMEDがファンレグラチニブの中国NDA受理と優先審査を発表、第II相登録試験の結果をサポート Benzinga 2025.12.29 22:52 (GMT+0) Open on Benzinga 共有 Facebook Twitter LinkedIn Pinterest Email 中国での第II相登録試験の結果に裏付けられたNDA — — 肝細胞癌に次いで2番目に多い肝臓癌の一種であり、一般的に長期生存率はより低い Other news Trump Approval Drops to 37% As Cost of Living Tops Voters' Priorities Global Interactive Q3 EPS $(0.16) Up From $(0.17) YoY, Sales $27.000 Down From $1.828K YoY 'Lutnick asked battery startup Pure Lithium to accept US takeover, documents and source say'- Reuters Exclusive Exicure Q3 Adj. EPS $(0.01) Up From $(0.39) YoY Momentus Q3 EPS $(0.40) Misses $(0.36) Estimate, Sales $4.816M Beat $2.600M Estimate 'Wonder Explores Sale of Food-Delivery Business Grubhub; Bankers Have Been In Contact With Walmart, Target, Kroger And Other Retailers About A Potential Purchase'- WSJ
'Lutnick asked battery startup Pure Lithium to accept US takeover, documents and source say'- Reuters Exclusive
'Wonder Explores Sale of Food-Delivery Business Grubhub; Bankers Have Been In Contact With Walmart, Target, Kroger And Other Retailers About A Potential Purchase'- WSJ